Stay updated on Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:27:28.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the impact assessment of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:37.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying conditions such as chronic atopic dermatitis and prior treatments. This change provides more specific information about the health conditions and treatment history required for study participants.
    Difference
    23%
    Check dated 2024-05-22T21:08:14.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T21:50:47.000Z thumbnail image

Stay in the know with updates to Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page.